Avera Pharmaceuticals

Avera identifies high-value clinical stage assets, acquires development and commercialization rights, conducts further development through important value-adding milestones, then partners or licenses these assets, with retained rights for specialty sales. Avera distinguishes itself from other development companies based on its breadth and depth of experience from pre-clinical to clinical development.

Avera will pursue in-licensing and partnering opportunities for both clinical stage (Phase 1-3) and near-IND compounds within its areas of therapeutic interest, by forming strategic alliances with established pharmaceutical companies, and by accessing its network of private and public research institutions. For further information regarding potential licensing opportunities please contact Business Development.

Avera’s clinical team has extensive drug development expertise in both large and small pharmaceutical companies. The Company works in close collaboration with contract research organizations that support the conduct of clinical development. Our philosophy and approach is to retain project leadership within Avera, while extending the capabilities necessary to conduct multicenter clinical trials in the US and abroad. In this way, our clinical team can efficiently manage the resources provided by our contractors, and act responsively when the need arises.

Where applicable, Avera conducts proof-of-concept studies across multiple indications in parallel, working opportunistically to maximize asset value in the shortest time possible. This multi-prong approach helps mitigate the inherent risks of drug developments, while maximizing the potential upside return on investment.

AV608: AV608 is currently under evaluation for Overactive Bladder and Irritable Bowel Syndrome. Following completion of these studies, Avera will seek a commercialization partner and ultimately develop its own specialty sales and marketing resources in anticipation of a market launch.

AV965: AV965 is currently completing Phase 1 development and studies are being planned to assess safety and pharmacokinetics in a patient population, with efficacy as a secondary outcome measure. Target indications are Cognitive Impairment Associated with Schizophrenia and Dementia. Avera plans to complete development of this asset through NDA filing, either alone or in collaboration with a partner. The Company expects to develop a psychiatry specialty sales and marketing effort and commercialize the asset for schizophrenia, potentially in collaboration with a partner.

Gantacurium Chloride: Avera has completed a Phase 2 clinical trial with Gantacurium Chloride for endotracheal intubation and is currently seeking to partner this asset.